Descriptive characteristics and χ2 tests for the 212 patients with breast cancer according to median MVD value when counted in 10 visual fields
| Total | ≤72.9 vessels/mm2 | >72.9 vessels/mm2 | χ2 | |
| Number of cases (%) | 212 (100.0) | 106 (50.0) | 106 (50.0) | |
| Median age at diagnosis, years (IQR) | 72 (64–78) | 73 (65–78) | 69.5 (61–78) | |
| Median follow-up time, years (IQR) | 4.6 (1.9–11.2) | 6.4 (3.0–12.7) | 3.2 (1.7–9.9) | |
| Median time to breast cancer death, years (IQR) | 2.4 (1.3–4.2) | 3.3 (1.3–8.1) | 2.1 (1.3–3.5) | |
| Age at diagnosis, years (%) | 0.003 | |||
| <60 | 31 | 7 (22.6) | 24 (77.4) | |
| 60–69 | 58 | 29 (50.0) | 29 (50.0) | |
| 70–79 | 75 | 47 (62.7) | 28 (37.3) | |
| ≥80 | 48 | 23 (47.9) | 25 (52.1) | |
| Type, n (%) | 0.211 | |||
| No special type | 149 | 79 (53.0) | 70 (47.0) | |
| Lobular | 13 | 4 (30.8) | 9 (69.2) | |
| Mucinous | 1 | 1 (100.0) | 0 (0.0) | |
| Medullary | 15 | 5 (33.3) | 10 (66.7) | |
| Papillary | 9 | 6 (66.7) | 3 (33.3) | |
| Metaplastic | 12 | 7 (58.3) | 5 (41.7) | |
| Other types | 13 | 4 (30.8) | 9 (69.2) | |
| Grade, n (%) | 0.046 | |||
| 1 | 6 | 6 (100.0) | 0 (0.0) | |
| 2 | 49 | 24 (49.0) | 25 (51.0) | |
| 3 | 157 | 76 (48.4) | 81 (51.6) | |
| Subtype, n (%) | <0.001 | |||
| Luminal A | 63 | 44 (69.8) | 19 (30.2) | |
| Luminal B (HER2–) | 0 | 0 | 0 | |
| Luminal B (HER2+) | 0 | 0 | 0 | |
| HER2 type | 61 | 25 (41.0) | 36 (59.0) | |
| 5NP | 27 | 6 (22.2) | 21 (77.8) | |
| BP | 61 | 31 (50.8) | 30 (49.2) | |
| Tumour diameter (mm), n (%) | 0.003 | |||
| ≤20 | 79 | 49 (62.0) | 30 (38.0) | |
| >20≤50 | 24 | 12 (50.0) | 12 (50.0) | |
| Uncertain, but ≥20 | 54 | 17 (31.5) | 37 (68.5) | |
| Uncertain* | 55 | 28 | 27 | |
| Lymph node status, n (%) | 0.100 | |||
| Negative | 80 | 47 (58.8) | 33 (41.3) | |
| Positive | 93 | 43 (46.2) | 50 (53.8) | |
| Unknown* | 39 | 16 | 23 | |
| Stage, n (%) | 0.137 | |||
| I | 92 | 46 (50.0) | 46 (50.0) | |
| II | 95 | 53 (55.8) | 42 (44.2) | |
| III | 15 | 4 (26.7) | 11 (73.3) | |
| IV | 9 | 3 (33.3) | 6 (66.7) | |
| Missing* | 1 | 0 | 1 |
*χ2 test does not include cases with uncertain, unknown or missing values.
BP, basal phenotype; HER2, human epidermal growth factor receptor 2; MVD, microvessel density; 5NP, five negative phenotype.